Mesoblast hosts webinar on Ryoncil’s role in acute graft-versus-host disease
AI Summary- Mesoblast hosted a webinar featuring Dr. Susan Prockop on Ryoncil and acute graft-versus-host disease.
- Ryoncil is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older.
- Mesoblast is developing additional cell therapies and holds more than 1,000 granted patents or applications.